Increased manufacturing capacity for Eli Lilly’s (LLY.N), opens new tab highly sought after weight-loss drug Zepbound drove the company to raise its annual sales forecast by $3 billion on Thursday, and its share jumped as much as 14%.
Lilly also raised its 2024 profit forecast and said sales of Zepbound crossed $1 billion for the first time in a quarter since its launch in late 2023.
The Zepbound milestone comes after Danish rival Novo Nordisk (NOVOb.CO), opens new tab reported a rare miss on quarterly sales of its weight-loss drug Wegovy and trimmed its full-year profit forecast.
Source:REUTER
Leave A Comment